Theratechnologies Inc (TH) Given New C$9.75 Price Target at National Bank Financial
Theratechnologies Inc (TSE:TH) had its price target hoisted by stock analysts at National Bank Financial from C$9.25 to C$9.75 in a research report issued to clients and investors on Friday, StockTargetPrices.com reports. The firm presently has an “outperform” rating on the stock. National Bank Financial’s price target would indicate a potential upside of 25.64% from the stock’s previous close. National Bank Financial also issued estimates for Theratechnologies’ Q3 2017 earnings at ($0.02) EPS and FY2017 earnings at ($0.16) EPS.
Separately, Scotiabank dropped their target price on shares of Theratechnologies from C$9.50 to C$9.25 and set an “outperform” rating for the company in a research report on Friday, September 29th.
Theratechnologies (TSE:TH) traded up 1.42% during mid-day trading on Friday, hitting $7.87. 90,081 shares of the stock were exchanged. The stock’s market capitalization is $585.65 million. The company has a 50-day moving average of $7.54 and a 200-day moving average of $7.16. Theratechnologies has a 52 week low of $2.61 and a 52 week high of $8.72.
Theratechnologies Company Profile
Theratechnologies Inc is a specialty pharmaceutical company. The Company addresses medical needs to promote healthy living among human immunodeficiency virus (HIV) patients. Its products include EGRIFTA and Ibalizumab. EGRIFTA (tesamorelin for injection) refers to tesamorelin and it is indicated for the reduction of excess abdominal fat in HIV infected patients with lipodystrophy.
Receive News & Ratings for Theratechnologies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies Inc and related companies with MarketBeat.com's FREE daily email newsletter.